This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.
Novartis has been at the forefront of CML research for years – significantly changing the prognosis for patients. ... with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).
patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP). ... The US Food and Drug Administration (FDA) has already granted asciminib a fast track designation in CML.
indications such as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
There has been some egregious behaviour in the industry in terms of drug pricing,” he said referring to the net price of CML drugs, which have tripled over the course of
Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).
Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation
More from news
Approximately 5 fully matching, plus 49 partially matching documents found.
as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and
Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.
Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Marie Little, Managing Director, OPEN Health Patient &Brand Communications takes 15 minutes to answer some key questions on healthcare advertising. 1. WHAT IS HEALTHCARE ADVERTISING IN A NUTSHELL? Healthcare advertising follows the same principals
We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... US. CML is a rare cancer affecting the white blood
expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017. .
new Chronic Myelogenous Leukaemia (CML) study in the US.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...